All In Biotech

Drug Trial Radar · NCT07876674

A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia

A Single-Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of SR604 Injection for Prophylactic Treatment in Patients With Hemophilia A or B With or Without Inhibitors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of prophylactic treatment with SR604 Injection in hemophilia A/B patients with or without inhibitors.

Conditions

  • Hemophilia A
  • Hemophilia A and B
  • Hemophilia B

Interventions

  • SR604Drug

    SR604 will be administered as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treated total annualized bleeding rate (ABR) over 28 weeks of treatmentTime frame: Through week 28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.